The new 125,000-square-foot Bluebird Bio facility in Durham, N.C., houses about 50 researchers, engineers and employees, with more anticipated to be added. The site will manufacture the biotech firm's lentiviral vector required for the development of its gene and chimeric antigen receptor T-cell therapies, including those used for multiple myeloma treatments.
Bluebird Bio's N.C. manufacturing, research facility now operational
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.